A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors (NCT06586957)
A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Who can join: Review the eligibility criteria below.
Location: University of Arkansas Medical School — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- University of Arkansas Medical School — Little Rock, Arkansas
- University of California - Los Angeles — Los Angeles, California
- UCSF — San Francisco, California
- SCRI at HealthOne — Denver, Colorado
- Florida Cancer Specialists & Research Institute — Lake Mary, Florida
- AdventHealth Cancer Institute — Orlando, Florida
- Emory Winship Cancer Institute — Atlanta, Georgia
- Augusta University — Augusta, Georgia
- University of Kansas — Fairway, Kansas
- Dana Farber Cancer Institute — Boston, Massachusetts
- John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey
- Sidney Kimmell Cancer Center - Jefferson Health — Philadelphia, Pennsylvania
- UPMC — Pittsburgh, Pennsylvania
- Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee
- NEXT Oncology — Austin, Texas
- UT Southwestern — Dallas, Texas
- Intermountain Health — Salt Lake City, Utah
- University of Virginia — Charlottesville, Virginia
- NEXT Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (302) 596-8654
Email: clinicaltrials@nikangtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.